Article source：Kexing Biopharm
Nov 11,2025
View：
198 
Recently, Kexing Biopharm (688136.SH) announced the publication of key research findings on its novel antibody fusion protein GB10 project—targeted at anti-choroidal neovascularization diseases—in the renowned international pharmacology journal Biomedicine & Pharmacotherapy. As a dual-pathway drug simultaneously targeting VEGF and Ang-2, GB10 offers significant advantages, including multi-target blockade, superior in vitro potency, enhanced in vivo efficacy, prolonged duration of action, and ultra-high-concentration formulations. These features highlight its strong clinical potential and commercial value.
Biomedicine & Pharmacotherapy is an international open-access journal published by Elsevier, established in 1982. Over more than three decades, it has earned substantial global influence and authority, with an impact factor of 7.5 in 2025.
Breakthrough Efficacy: Dual-Target Inhibition Demonstrates Therapeutic Advantages
In clinical practice, anti-vascular endothelial growth factor (VEGF) therapies have proven effective for treating neovascular eye diseases.
Kexing Biopharm developed GB10, a novel multi-target antibody fusion protein employing a dual-strategy approach: targeting and inhibiting the two key pathogenic factors, VEGF and Ang-2, while formulating a high-concentration preparation (140 mg/mL). This innovation provides patients with neovascular eye diseases more effective and longer-lasting treatment options.
In Vitro Studies: Research data demonstrate GB10's exceptional biological activity in vitro:
· VEGF blockade potency is 7.5 times that of the reference drug;
· Ang-2 blockade potency is 94 times that of the reference drug;
· It exhibits marked superiority in HUVEC proliferation and tube formation assays.
In Vivo Studies: In a laser-induced choroidal neovascularization model in cynomolgus monkeys, GB10 displayed sustained and potent in vivo efficacy:
· The high-dose group achieved complete lesion regression;
· The low-dose group maintained significant efficacy through Day 21 post-treatment;
· Overall durability surpassed that of the reference drug.
Pharmacokinetic studies revealed that GB10 has a half-life of 59.4 hours in rabbit vitreous humor, and the successful development of a 140 mg/mL ultra-high-concentration formulation could extend the current 4-8 week treatment interval to over 12 weeks, greatly improving patient experience and adherence.
Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly, with risks escalating for those over 60. As global aging accelerates and awareness of eye health grows, the AMD drug market continues to expand.
The GB10 project represents a core pipeline asset in Kexing Biopharm's ophthalmology portfolio. As development of the GB10 project progresses, it is bringing benefits to more patients in the future.
About Kexing Biopharm
Kexing Biopharm (Stock Code: 688136.SH) is a multinational biopharmaceutical enterprise that engages in the R&D, manufacture and sales of innovative medicines of distinct modalities including recombinant proteins, antibodies, and cellular/gene therapies.
Through building cutting-edge technology platforms to advance the development of novel targeted therapies and drug delivery systems, Kexing Biopharm strives to address unmet clinical needs in the areas of oncology, autoimmune and antiviral treatment, creating a significant and meaningful positive impact on patients' lives.
By adhering to the platform development model driven by the twin engines of “Innovation & Internationalization”, Kexing Biopharm is committed to becoming a world leader in high-quality biopharmaceuticals, improving the health of patients worldwide.
BACK TO LIST
Jul 31,2024
